Is TXG Worth Buying in 2026?

10x Genomics, Inc. Class A Common Stock

STOCK LABORATORY ANALYTICAL INSTRUMENTS Updated 2026-05-24

Here’s whether 10x Genomics, Inc. Class A Common Stock (TXG) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.64% over 10 days); RSI 61 — healthy momentum range; strong 1-year return of +177.3%; 3-month momentum positive (+24.0%). Currently 10.5% off its 52-week high. Score: +7/7.

Ready to act on this? 📈 Trade on Webull

TXG is in a confirmed uptrend, trading above both its 50-day ($21.70) and 200-day ($17.60) moving averages. An RSI of 61.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +177.3% compares to +27.9% for SPY (beat the market by 149.4%).

$10,000 invested 1 year ago → $27,728 today
vs. S&P 500 (SPY) — same period beat market by 149.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($17.60)
Above 50-day MA ($21.70)
RSI(14) neutral zone (30–70) — currently 61.1
Positive return (+177.3%)
!Within 10% of period high (−10.5%)
Period Range $23.68
$8.07 $26.45
RSI (14) 61.1
0 · OversoldOverbought · 100

Key Metrics

Price$23.68
Period Return+177.3%
Period High$26.45
Period Low$8.07
Drawdown−10.5%
MA-50$21.70
MA-200$17.60
RSI (14)61.1
Avg Volume (30d)2.8M
vs. SPYbeat by 149.4%
Return Rank#137 of 1236

Trade TXG

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers